Pear Bio valuation, funding and investors
Pear Bio works in personalized cancer testing services, based in Natick, United States. Founded in 2017, it has about 9 employees.
VALUATION · TODAY
$16.7M −37% after Series A
Range $8.64M – $48.6M · Grade CTODAY
+12 MO
$100M
$200M
$300M
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series A $14.0M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY9 employees
−10%6m growth
−18%1y growth
−78%2y growth
25
50
Data from Mar 2022
Predicted in 1 yr $10.5M −37% vs today
Predicted next raise $16.1M if a round comes
Winding-down probability 97%
- Last round
- Series A · $14.0M · May 2023
- Valuation at last round
- $77.8M · implied
- Headcount
- 9 · shrinking
- Grade
- C
- Founded
- 2017
Pear Bio valuation today
VCMC values Pear Bio at $16.7M today, with a range of $8.64M to $48.6M and a grade of C. The valuation starts from its last funding round, a Series A round in May 2023.
Valuation by date (120 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $17.1M | $6.21M – $46.9M | $19.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $17.2M | $6.27M – $47.3M | $19.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $17.4M | $6.32M – $47.7M | $19.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $17.5M | $6.38M – $48.2M | $19.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $17.7M | $6.44M – $48.6M | $19.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $17.8M | $6.50M – $49.0M | $19.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $18.0M | $6.56M – $49.5M | $19.9M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $18.2M | $6.62M – $49.9M | $20.0M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $18.3M | $6.68M – $50.4M | $20.2M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $18.5M | $6.74M – $50.8M | $20.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $18.7M | $6.80M – $51.3M | $20.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $18.8M | $6.86M – $51.7M | $20.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $19.0M | $6.92M – $52.2M | $20.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $19.2M | $6.97M – $52.6M | $20.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $19.3M | $7.02M – $53.0M | $21.1M (+9%) | before first round | 16 | unknown | D | 0% |
| 1 Apr 2022 | $19.4M | $7.07M – $53.4M | $21.2M (+9%) | before first round | 16 | unknown | D | 0% |
| 1 May 2022 | $19.6M | $7.12M – $53.8M | $21.4M (+9%) | before first round | 16 | unknown | D | 0% |
| 1 Jun 2022 | $19.7M | $7.18M – $54.2M | $21.5M (+9%) | before first round | 16 | unknown | D | 0% |
| 1 Jul 2022 | $19.9M | $7.23M – $54.6M | $21.7M (+9%) | before first round | 16 | unknown | D | 0% |
| 1 Aug 2022 | $20.0M | $7.28M – $55.0M | $21.2M (+6%) | before first round | 16 | unknown | D | 0% |
| 1 Sep 2022 | $20.2M | $7.34M – $55.4M | $20.8M (+3%) | before first round | 16 | unknown | D | 0% |
| 1 Oct 2022 | $20.3M | $7.39M – $55.8M | $20.3M (0%) | before first round | 16 | unknown | D | 0% |
| 1 Nov 2022 | $20.5M | $7.45M – $56.2M | $19.9M (-3%) | before first round | 16 | unknown | D | 0% |
| 1 Dec 2022 | $20.6M | $7.50M – $56.6M | $19.5M (-6%) | before first round | 16 | unknown | D | 0% |
| 1 Jan 2023 | $30.2M | $12.9M – $60.0M | $28.4M (-6%) | before first round | 22 | growing | C | 0% |
| 1 Feb 2023 | $30.5M | $13.0M – $60.5M | $27.9M (-9%) | before first round | 22 | growing | C | 0% |
| 1 Mar 2023 | $30.7M | $13.1M – $60.9M | $27.4M (-11%) | before first round | 22 | growing | C | 0% |
| 1 Apr 2023 | $30.9M | $13.2M – $61.4M | $26.9M (-13%) | before first round | 22 | growing | C | 0% |
| 1 May 2023 | $31.1M | $13.3M – $61.8M | $26.4M (-15%) | before first round | 22 | growing | C | 0% |
| 16 May 2023 | $77.9M | $51.1M – $213M | $140M (+80%) | after a round | 22 | growing | C | 0% |
| 1 Jun 2023 | $79.9M | $51.1M – $213M | $140M (+75%) | after a round | 22 | growing | C | 0% |
| 1 Jul 2023 | $83.9M | $51.1M – $213M | $140M (+67%) | after a round | 22 | growing | C | 0% |
| 1 Aug 2023 | $88.2M | $51.1M – $213M | $140M (+59%) | after a round | 22 | growing | C | 0% |
| 1 Sep 2023 | $92.7M | $51.1M – $213M | $140M (+51%) | after a round | 22 | growing | C | 0% |
| 1 Oct 2023 | $99.3M | $53.9M – $225M | $148M (+49%) | after a round | 28 | up | C | 0% |
| 1 Nov 2023 | $105M | $53.9M – $225M | $148M (+41%) | after a round | 28 | up | C | 0% |
| 1 Dec 2023 | $110M | $53.9M – $225M | $148M (+34%) | after a round | 28 | up | C | 0% |
| 1 Jan 2024 | $117M | $53.9M – $225M | $148M (+27%) | after a round | 28 | up | C | 0% |
| 1 Feb 2024 | $127M | $56.2M – $234M | $154M (+21%) | after a round | 34 | growing | C | 0% |
| 1 Mar 2024 | $135M | $57.0M – $237M | $156M (+15%) | after a round | 36 | growing | C | 0% |
| 1 Apr 2024 | $144M | $57.0M – $237M | $156M (+9%) | after a round | 36 | growing | C | 0% |
| 1 May 2024 | $152M | $57.0M – $237M | $156M (+3%) | after a round | 36 | growing | C | 0% |
| 1 Jun 2024 | $156M | $57.4M – $237M | $156M (0%) | after a round | 36 | growing | C | 0% |
| 1 Jul 2024 | $156M | $58.2M – $237M | $156M (0%) | after a round | 36 | growing | C | 0% |
| 1 Aug 2024 | $161M | $60.8M – $244M | $161M (0%) | after a round | 41 | growing | C | 0% |
| 1 Sep 2024 | $161M | $61.7M – $244M | $161M (0%) | after a round | 41 | growing | C | 0% |
| 1 Oct 2024 | $161M | $62.5M – $244M | $161M (0%) | after a round | 41 | growing | C | 0% |
| 1 Nov 2024 | $156M | $54.1M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 Dec 2024 | $156M | $53.6M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 Jan 2025 | $156M | $53.1M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 Feb 2025 | $156M | $52.6M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 Mar 2025 | $156M | $52.1M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 Apr 2025 | $156M | $51.6M – $237M | $156M (0%) | after a round | 36 | up | C | 0% |
| 1 May 2025 | $156M | $32.0M – $237M | $156M (0%) | after a round | 36 | flat | D | 0% |
| 1 Jun 2025 | $156M | $30.4M – $237M | $155M (0%) | after a round | 36 | flat | D | 0% |
| 1 Jul 2025 | $156M | $28.9M – $237M | $155M (-1%) | after a round | 36 | flat | D | 0% |
| 1 Aug 2025 | $45.3M | $25.1M – $101M | $26.2M (-42%) | after a round | 24 | shrinking | C | 97% |
| 1 Sep 2025 | $43.5M | $23.9M – $99.2M | $25.0M (-42%) | after a round | 24 | shrinking | C | 97% |
| 1 Oct 2025 | $35.2M | $19.1M – $82.5M | $20.2M (-43%) | after a round | 11 | shrinking | C | 97% |
| 1 Nov 2025 | $33.8M | $18.2M – $81.3M | $19.3M (-43%) | after a round | 11 | shrinking | C | 97% |
| 1 Dec 2025 | $32.5M | $17.3M – $80.3M | $18.5M (-43%) | after a round | 11 | shrinking | C | 97% |
| 1 Jan 2026 | $31.3M | $16.5M – $79.1M | $17.6M (-44%) | after a round | 11 | shrinking | C | 97% |
| 1 Feb 2026 | $30.0M | $15.6M – $78.0M | $16.9M (-44%) | after a round | 11 | shrinking | C | 97% |
| 1 Mar 2026 | $28.9M | $14.9M – $77.1M | $16.2M (-44%) | after a round | 11 | shrinking | C | 97% |
| 1 Apr 2026 | $27.2M | $13.9M – $74.4M | $15.2M (-44%) | after a round | 10 | shrinking | C | 97% |
| 1 May 2026 | $26.2M | $13.2M – $73.4M | $14.5M (-45%) | after a round | 10 | shrinking | C | 97% |
| 1 Jun 2026 | $23.6M | $12.6M – $57.8M | $14.2M (-40%) | after a round | 10 | shrinking | C | 97% |
| 1 Jul 2026 | $22.6M | $12.0M – $56.0M | $13.6M (-40%) | after a round | 10 | shrinking | C | 97% |
| 1 Aug 2026 | $21.6M | $11.4M – $54.3M | $13.0M (-40%) | after a round | 10 | shrinking | C | 97% |
| 1 Sep 2026 | $20.2M | $10.6M – $51.3M | $12.1M (-40%) | after a round | 9 | shrinking | C | 97% |
| 1 Oct 2026 | $19.3M | $10.1M – $49.8M | $11.6M (-40%) | after a round | 9 | shrinking | C | 97% |
| 24 Oct 2026 | $16.7M | $8.64M – $48.6M | $10.5M (-37%) | after a round | 9 | shrinking | C | 97% |
Key facts about Pear Bio
- Founded
- 2017
- Headquarters
- Natick, United States
- Employees
- about 9 -18% in a year
- Total raised
- $14M
- Funding rounds
- 1
- Last round
- Series A May 2023
Pear Bio was founded in 2017 by Duleek Ranatunga and William Lin.
Pear Bio funding history
Pear Bio has 1 funding round on record, from May 2023 to May 2023, $14M in total. None disclosed a valuation.
Series A 15 May 2023
Led by Octopus Ventures; with Hoxton Ventures, Crista Galli Ventures, SOSV, Fly Ventures, Compound.
$14M
Pear Bio investors
6 investors have backed Pear Bio; Octopus Ventures led at least one round.
What Pear Bio does
Pear Bio works in biotechnology, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Pear Bio is a United States company engaged in cancer precision medicine, focusing on personalized testing and therapeutics for patients with hard-to-treat cancers. The company operates a platform that includes tumor biopsies, 3D immune-microtumor generation, and multi-omic analysis to identify new targets and develop therapeutics. Pear Bio also engages in drug discovery for a range of indications, including breast and lung cancer, and serves patients in the United States and the United Kingdom.
Description from Veridion's company data.
Products and services
- Personalized Cancer Testing Services
- Precision Medicine Therapeutics Development
- Tumor Biopsy Analysis Services
- 3D Immune-Microtumor Model Development
- Multi-Omic Data Analysis Services
- Genetic and Epigenetic Target Identification
- Drug Candidate Discovery and Development
- Clinical Trial Participation Services
- Patient Response Prediction Services
- Breast and Lung Cancer Therapeutics Development
- Precision Medicine Platform Solutions
- Flexible Personalized Testing Solutions
- Advanced 3D Cell Culture System Utilization
- Precision Medicine Consulting Services
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- 3D Immune-Microtumor Generation
- Advanced Multi-Omic Analysis
- 3D Cell Culture Systems
Business model
- Business-to-Business
- Service Provider
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 50% match
- 621511 Medical Laboratories 50% match
Questions about Pear Bio
What is Pear Bio worth?
Valuation $16.7M (range $8.64M to $48.6M), as of 24 Oct 2026.
Has Pear Bio raised money?
Pear Bio has 1 funding round on record, from May 2023 to May 2023, $14M in total. None disclosed a valuation.
Who has invested in Pear Bio?
Octopus Ventures, Compound, Crista Galli Ventures, Fly Ventures, Hoxton Ventures and SOSV. Lead investors include Octopus Ventures.
How many people work at Pear Bio?
About 9, down 18% over the last year. Headcount rose from 16 in Mar 2022 to 41 in Aug 2024, then fell to 9 in Sep 2026.
What does Pear Bio do?
Pear Bio works in biotechnology, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are personalized cancer testing services, precision medicine therapeutics development and tumor biopsy analysis services.
When was Pear Bio founded, and where is it based?
Pear Bio was founded in 2017 and is based in Natick, United States. It has about 9 employees, down 18% over the last year.